Related Experiment Video

Updated: Aug 6, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

[Acute community-acquired pneumonia. A review of clinical trials]

C Chidiac1

  • 1Service des maladies infectieuses et tropicales et Inserm EA230, hôpital de la Croix-Rousse, 103, grande rue de la Croix-Rousse, 69317 Lyon, France. christian.chidiac@chu-lyon.fr

Medecine Et Maladies Infectieuses
|August 1, 2006
PubMed

Insights

High-dose amoxicillin (1g tid) is effective for pneumococcal community-acquired pneumonia (CAP), even with macrolide resistance. Other antibiotics like telithromycin, pristinamycin, and fluoroquinolones have specific uses in CAP treatment.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Context:

  • Community-acquired pneumonia (CAP) treatment guidelines are debated.
  • Streptococcus pneumoniae resistance to macrolides is a significant clinical concern.
  • High-dose amoxicillin demonstrates sustained activity against resistant strains.

Purpose:

  • To review clinical trials on CAP antibiotic treatment from 1999 to 2005.
  • To evaluate the efficacy of various antibiotics for CAP.
  • To identify optimal treatment strategies for pneumococcal CAP.

Summary:

  • A review of 16 clinical trials identified amoxicillin (1g tid) as the preferred treatment for pneumococcal CAP.
  • Telithromycin and pristinamycin are suitable for mild to moderate CAP.
  • Anti-pneumococcal fluoroquinolones (levofloxacin, moxifloxacin) are options for at-risk patients, with levofloxacin studied in severe CAP and Legionnaires' disease.

Impact:

  • Provides evidence supporting high-dose amoxicillin as a primary treatment for pneumococcal CAP.
  • Clarifies the roles of alternative antibiotics in specific CAP patient populations.
  • Informs clinical decision-making for optimizing antibiotic selection in CAP.

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.